The concomitant usage of buprenorphine and CYP3A4 inducers can minimize the plasma focus of buprenorphine [see CLINICAL PHARMACOLOGY], likely resulting in lowered efficacy or onset of a withdrawal syndrome in individuals who have formulated Actual physical dependence to buprenorphine.The estimated background risks of big birth defects and miscarria